Today Illumina; tomorrow the world? Where the acquisition might really take Roche
This article was originally published in Scrip
Hoffmann-La Roche wants to acquire the San Diego-based gene sequencing and array diagnostic company leader Illumina and the fact that it is willing to engage in a hostile takeover of the company and start the bidding in that process at a 64% premium to Illumina's most recent stock price indicated that the Swiss giant is really serious.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.